QRL-201 - Dose 7 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 1 |
2. 筋萎縮性側索硬化症
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05633459 (ClinicalTrials.gov) | December 16, 2022 | 21/11/2022 | A Study Evaluating the Safety and Tolerability of QRL-201 in ALS | A Multi-Center, Randomized, Double-Blind Placebo Controlled Multiple-Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: QRL-201 - Dose 1;Drug: QRL-201 - Dose 2;Drug: QRL-201 - Dose 3;Drug: QRL-201 - Dose 4;Drug: QRL-201 - Dose 5;Drug: QRL-201 - Dose 6;Drug: QRL-201 - Dose 7;Drug: QRL-201- Dose 8 | QurAlis Corporation | NULL | Recruiting | 18 Years | 80 Years | All | 64 | Phase 1 | Canada |